Glaukos Corporation (GKOS): Price and Financial Metrics

Glaukos Corporation (GKOS)

Today's Latest Price: $66.76 USD

0.26 (-0.39%)

Updated Nov 24 7:00pm

Add GKOS to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 143 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

GKOS Stock Summary

  • GKOS's price/sales ratio is 13.85; that's higher than the P/S ratio of 88.84% of US stocks.
  • With a year-over-year growth in debt of 231.57%, GLAUKOS Corp's debt growth rate surpasses 93.4% of about US stocks.
  • Over the past twelve months, GKOS has reported earnings growth of 744.23%, putting it ahead of 98.21% of US stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to GLAUKOS Corp are MTBC, NEWR, LC, EB, and VCYT.
  • GKOS's SEC filings can be seen here. And to visit GLAUKOS Corp's official web site, go to

GKOS Stock Price Chart Interactive Chart >

Price chart for GKOS

GKOS Price/Volume Stats

Current price $66.76 52-week high $70.96
Prev. close $67.02 52-week low $23.31
Day low $66.67 Volume 261,245
Day high $68.54 Avg. volume 706,550
50-day MA $56.16 Dividend yield N/A
200-day MA $44.89 Market Cap 3.00B

Glaukos Corporation (GKOS) Company Bio

Glaukos Corporation develops and commercializes products and procedures designed for the treatment of glaucoma. The company was founded in 1998 and is based in Laguna Hills, California.

GKOS Latest News Stream

Event/Time News Detail
Loading, please wait...

GKOS Latest Social Stream

Loading social stream, please wait...

View Full GKOS Social Stream

Latest GKOS News From Around the Web

Below are the latest news stories about GLAUKOS Corp that investors may wish to consider to help them evaluate GKOS as an investment opportunity.

Glaukos Is Still A Good Long-Term Value Despite A Tough 2020

Glaukos (GKOS) is a long-term holding of mine that has been heavily impacted by the COVID-19 pandemic. Given that the vast majority of Glaukos’ revenue comes from elective surgery, many of the procedures that would have led to product sales for the company just haven’t been taking place. I last...

Andy Jones on Seeking Alpha | August 20, 2020

Glaukos Corporation (GKOS) Tom Burns on Q2 2020 Results - Earnings Call Transcript

Glaukos Corporation (GKOS) Q2 2020 Earnings Conference Call August 6, 2020 16:30 ET Company Participants Chris Lewis - Director of Investor Relations, Corporate Strategy & Development Tom Burns - President & Chief Executive Officer Joe Gilliam - Chief Financial Officer Chris Calcaterra - Chief Operating Officer Conference Call Participants Brian...

SA Transcripts on Seeking Alpha | August 9, 2020

Glaukos (GKOS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Glaukos (GKOS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | July 30, 2020

Glaukos Corporation to Release Second Quarter 2020 Financial Results after Market Close on August 6

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2020 financial results after the market close on Thursday, August 6, 2020. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PDT (4:30 p.m. EDT) on August 6, 2020.

Yahoo | July 20, 2020

Here is What Hedge Funds Think About Glaukos Corporation (GKOS)

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]

Yahoo | June 28, 2020

Read More 'GKOS' Stories Here

GKOS Price Returns

1-mo 15.60%
3-mo 50.53%
6-mo 71.27%
1-year 5.50%
3-year 163.98%
5-year 154.23%
YTD 22.56%
2019 -3.03%
2018 118.99%
2017 -25.22%
2016 38.92%
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8229 seconds.